14 · Verified Catalyst Calendar
Verified Catalyst Calendar
Bookmarks need a Mind Club sign-in. How sign-in works
Verified Catalyst Calendar across your briefsTwo goal dates this weekend, BBP-418 the day after Thanksgiving and a busy 11.30, then the FOMC, ASH and a run of December goal dates. Eighteen of 22 dates are confirmed at a company, agency or organizer source.
| Date | Event | Who | Confirmed at |
|---|---|---|---|
| Sun 11.22 | Goal date, molgramostim in autoimmune pulmonary alveolar proteinosis, extended after a major amendment | Savara | Aggregator |
| Sun 11.22 | Goal date, deramiocel in Duchenne muscular dystrophy, extended from 08.22 after a major amendment | Capricor | Company |
| Fri 11.27 | Goal date, BBP-418 in limb-girdle muscular dystrophy 2I/R9, priority review | BridgeBio | Company |
| Mon 11.30 | Goal date, giredestrant as adjuvant therapy in early breast cancer (lidERA), priority review | Roche | Company |
| Mon 11.30 | Goal date, povetacicept in IgA nephropathy, accelerated approval | Vertex | Company |
| Mon 11.30 | Goal date, bezuclastinib with sunitinib in GIST | Cogent | Company |
| Mon 11.30 | Deadline for CMS to publish any 2028 negotiated or renegotiated prices | CMS | Gov |
| Wed 12.02 | PIVOT-006 presentation at SUO | CG Oncology | Press |
| Thu 12.03 | Goal date, zanzalintinib with atezolizumab in previously treated metastatic colorectal cancer | Exelixis | Company |
| Mon 12.07 | ASH late-breaking abstracts posted, 9:00 am ET | ASH | Organizer |
| Tue 12.08 to Wed 12.09 | FOMC meeting, with projections; rate decision 12.09 | Federal Reserve | Gov |
| Sat 12.12 | Goal date, imsidolimab in generalized pustular psoriasis | Vanda | Press |
| Sat 12.12 to Tue 12.15 | ASH Annual Meeting, New Orleans | ASH | Organizer |
| Sat 12.12 | Anito-cel orals at ASH: iMMagine-1 update and newly diagnosed myeloma | Gilead | Company |
| Fri 12.18 | Goal date, CAM2029 (octreotide depot) in acromegaly, after resubmission | Camurus | Company |
| Sat 12.19 | Goal date, imlifidase for kidney transplant desensitization | Hansa Biopharma | Company |
| Tue 12.22 | Goal date, lorundrostat in hypertension | Mineralys | Company |
| Wed 12.23 | Goal date, anito-cel in relapsed or refractory multiple myeloma | Gilead | Company |
| Sun 12.27 | Goal date, relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies | Praxis | Company |
| Sun 12.27 | Goal date, fast-acting meloxicam (MR-107A-02) in acute pain | Viatris | Aggregator |
| Wed 12.30 | Goal date, bezuclastinib in nonadvanced systemic mastocytosis | Cogent | Company |
| Wed 12.30 | Goal date, SL1009 (sodium dichloroacetate) in pyruvate dehydrogenase complex deficiency, after resubmission | Saol Therapeutics | Company |
Confirmed today: Capricor 8-K (08.24) (opens another website in a new tab); BridgeBio third quarter report (10.29) (opens another website in a new tab); Vertex (06.01) (opens another website in a new tab); Cogent (11.05) (opens another website in a new tab); Gilead (11.04) (opens another website in a new tab); Praxis (11.09) (opens another website in a new tab) Co; Federal Reserve FOMC calendar (opens another website in a new tab) Gov; Savara via Panabee (opens another website in a new tab) and Viatris via a PR Newswire roundup (opens another website in a new tab) Data. CMS IPAY 2028 guidance fact sheet (opens another website in a new tab) Gov. Carried from the 11.19 edition, not reopened today: Roche, SUO, Exelixis, ASH, Vanda, Camurus, Hansa Biopharma, Mineralys and Saol. Calendar dates can move without notice.